This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Sukumar Sakamuri, PhD
Chief Technology Officer at Aro Biotherapeutics


Sukumar Sakamuri is currently working as Chief Technology Officer at Aro Biotherapeutics, Philadelphia, USA. He has over 20 years of drug discovery experience in biotech industry and proven entrepreneurial leadership, co-founding a biotech company Tollnine. He is an expert in developing novel drug discovery technology platforms including oligonucleotides, antibody drug conjugates, peptides and small molecules. Prior to joining Aro, Dr. Sakamuri has worked in increasing responsibilities at Ambrx, Tollnine, Solstice, Traversa and CovX. He has advanced multiple programs in immuno-oncology, oncology, rare and genetic diseases, metabolic and diabetes indications into preclinical and clinical development. Dr. Sakamuri is an inventor and author of over 45 patents, patent applications and publications. He conducted postdoctoral research in medicinal chemistry at Georgetown University, Washington, DC and holds a Ph.D. in organic chemistry from the Indian Institute of Chemical Technology, India.

Agenda Sessions

  • Centyrin-siRNA Conjugates: A Novel Therapeutic Modality for Extra-hepatic Targeting